Opaleye Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Opaleye Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-500,000	Closed	-$9.25M	–	46
2017 Q3	$9.25M	Buy	500,000 +50,000	+11%	+$836K	3.27%	8
2017 Q2	$7.61M	Buy	450,000 +10,000	+2%	+$152K	3.18%	8
2017 Q1	$5.87M	Buy	440,000 +110,000	+33%	+$1.72M	2.92%	10
2016 Q4	$4.97M	Buy	+330,000	New	+$4.36M	2.93%	12
2015 Q4	–	Sell	-160,000	Closed	-$2.63M	–	56
2015 Q3	$2.63M	Buy	+160,000	New	+$3.28M	1.29%	31

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management's MNTA Position: Q4 2017 in Review

Opaleye Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2017, closing a stake of 500,000 shares — an estimated $9.25M sold.

Opaleye Management first reported a position in MNTA in Q3 2015 and held it in 5 quarters. The position peaked at $9.25M in Q3 2017. 166 funds tracked by Wall St. Rank hold MNTA as of Q4 2017.

Opaleye Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Opaleye Management sold 500,000 Momenta Pharmaceuticals, Inc. shares in Q4 2017, an estimated $9.25M.
Opaleye Management first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2015 and held it in 5 quarters.
Opaleye Management's Momenta Pharmaceuticals, Inc. position peaked at $9.25M in Q3 2017.
166 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.